Physician profile
Christ Ticoras
NPI 1821099615
$6,306.81
in general payments reported to CMS, 2019-2025
20 companies · $88.53 in 2025
The $88.53 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.77 · 2020: $131 · 2021: $489 · 2022: $499 · 2023: $3,496 · 2024: $1,514 · 2025: $88.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $1,723 · Travel and Lodging: $365 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $1,723.33 |
| Travel and Lodging | $364.56 |
| Education | $210.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,731.95 | 2019-2025 | Ilumya |
| Janssen Biotech, INC. | $579.41 | 2020-2024 | Tremfya |
| Dermavant Sciences, INC. | $388.02 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $350.11 | 2020-2024 | Oracea, Aklief |
| Abbvie INC. | $306.77 | 2022-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $160.19 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $124.89 | 2024 | Zoryve |
| Journey Medical Corporation | $108.20 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $94.72 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $88.10 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.48 | 2022-2024 | Sotyktu |
| Allergan, INC. | $67.01 | 2021-2022 | |
| Genzyme Corporation | $65.88 | 2019-2024 | |
| Encore Dermatology INC. | $36.72 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $32.93 | 2019-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $28.60 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $24.09 | 2019-2020 | |
| Amgen INC. | $20.00 | 2024 | Otezla |
| Organon LLC | $16.60 | 2025 | Vtama |
| Incyte Corporation | $13.14 | 2023 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christ Ticoras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.